Evaluation of the drug utilization of biosimilar medicinal products containing monoclonal antibodies: A systematic review

Author:

Yordanov Emanuil1,Parvova Iva2,Hristov Emil1ORCID,Petkova Valentina3

Affiliation:

1. Laboratory of Social Pharmacy, Faculty of Chemistry and Pharmacy, Sofia University “Saint Kliment Ohridski, Bulgaria

2. Clinic of Rheumatology, Department of Internal Medicine, Medical University of Sofia, Bulgaria

3. Faculty of Pharmacy, Medical University of Sofia, Bulgaria

Abstract

Aim: The objective is to study the availability and affordability of biosimilar medicinal products containing monoclonal antibodies, measure their drug utilization, and evaluate the rational drug use globally through analysis and systematic review of scientific articles published in the scientific literature. Materials and methods: The documentary analysis of scientific publications was carried out by specific keywords in MEDLINE database, Central Medical Library, and national peer-reviewed scientific journals in Bulgaria for the period from January 2008 to May 2020. 100 scientific publications have been found for a period of 12 years. Articles were selected according to PRISMA. Analyses include 17 articles that fully meet the preset criteria. Descriptive and variational analyses were carried out as basic statistical analyses. Mean values, standard deviation, minimum, maximum, and 95% confidence intervals have been determined. Results and discussion: Studies on this topic in EU Member States are obviously of interest, but publication activity is not high—only 17 scientific publications over a 12-year period. All 17 studies reflect cost savings after switching from a reference biological medicinal product to a biosimilar medicinal product, and the reduction in budgetary costs as a weighted average is about 30% of the total budgetary costs of biological therapies for the first 5 years. All 17 studies have reported that the use of biosimilar medicinal products is rather low. Although the quality, safety, and efficacy of biosimilar medicinal products have been unequivocally established, their introduction to the market is still insufficient.

Publisher

SAGE Publications

Subject

Pharmaceutical Science

Reference28 articles.

1. WHO. Resolution. WHA60.16. Progress in the rational use of medicines. 2021. The Sixtieth World Health Assembly, [Cited 2021 June 23]. WHO. Available from: https://apps.who.int/gb/ebwha/pdf_files/WHASSA_WHA60-Rec1/E/reso-60-en.pdf?ua=1#page=27.

2. Principles of Irrational Drug Therapy

3. Availability, affordability and drug utilization of biosimilar medicinal products, containing monoclonal antibodies in Bulgaria

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3